FDA approves Oridion's breath test device:
This article was originally published in Clinica
Executive Summary
The US FDA has approved Oridion Systems' 510(k) application for its BreathID Breath Testing device. The Jerusalem, Israel company says it will begin marketing the device as soon as it obtains FDA approval for the urea tablet that forms part of the device's first application, the 13C urea Helicobacter pylori breath test. The test will enable physicians to diagnose the bacteria in a single office visit, without the need to send samples to a central laboratory.
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.